Alkem launches Pertuza in India to treat HER2-positive breast cancer EP News Bureau Sep 23, 2025 Alkem Laboratories has announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment…
Mylan and Biocon to present phase-III trastuzumab biosimilar data at ASCO annual meeting Usha Sharma Jun 6, 2016 HERITAGE study shows comparable efficacy, safety and immunogenicity to branded trastuzumab in HER2-positive metastatic breast…
